Brandywine Global Investment Management LLC Boosts Stock Position in Medtronic PLC $MDT

Brandywine Global Investment Management LLC grew its stake in Medtronic PLC (NYSE:MDT) by 4.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,584,743 shares of the medical technology company’s stock after acquiring an additional 64,466 shares during the quarter. Medtronic makes up approximately 1.0% of Brandywine Global Investment Management LLC’s investment portfolio, making the stock its 20th biggest position. Brandywine Global Investment Management LLC’s holdings in Medtronic were worth $152,230,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Lodestone Wealth Management LLC purchased a new position in Medtronic in the fourth quarter worth approximately $27,000. Anfield Capital Management LLC grew its position in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Board of the Pension Protection Fund purchased a new position in Medtronic in the fourth quarter worth approximately $29,000. GoalVest Advisory LLC purchased a new position in Medtronic in the fourth quarter worth approximately $29,000. Finally, Imprint Wealth LLC purchased a new position in Medtronic in the third quarter worth approximately $31,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Robert W. Baird lowered their price objective on Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday. Wells Fargo & Company lowered their price objective on Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday. Weiss Ratings lowered Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Truist Financial lowered their price objective on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research report on Thursday. Finally, Piper Sandler lowered their price objective on Medtronic from $91.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday. Seventeen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $99.00.

Medtronic Trading Down 0.0%

Shares of MDT stock opened at $81.66 on Monday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a 50 day moving average price of $81.46 and a 200 day moving average price of $92.01. The stock has a market capitalization of $104.84 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 1.99 and a beta of 0.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same period in the prior year, the business earned $1.62 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts predict that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. Medtronic’s payout ratio is 76.14%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
• Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
• Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).